Financial Times and McKinsey Business Book of the Year
'I couldn’t put down this thriller . . . the perfect book to read by the fire this winter.' Bill Gates, '5 books I loved in 2018'
WINNER OF THE FINANCIAL TIMES/MCKINSEY BUSINESS BOOK OF THE YEAR AWARD 2018
The full inside story of the breathtaking rise and shocking collapse of Theranos, the multibillion-dollar biotech startup, by the prize-winning journalist who first broke the story and pursued it to the end, despite pressure from its charismatic CEO and threats by her lawyers.
In 2014, Theranos founder and CEO Elizabeth Holmes was widely seen as the female Steve Jobs: a brilliant Stanford dropout whose startup "unicorn" promised to revolutionize the medical industry with a machine that would make blood testing significantly faster and easier. Backed by investors such as Larry Ellison and Tim Draper, Theranos sold shares in a fundraising round that valued the company at more than $9 billion, putting Holmes's worth at an estimated $4.7 billion. There was just one problem: The technology didn't work.
In Bad Blood, John Carreyrou tells the riveting story of the biggest corporate fraud since Enron, a tale of ambition and hubris set amid the bold promises of Silicon Valley.
Now to be adapted into a film, with Jennifer Lawrence to star.
'Chilling . . . Reads like a West Coast version of All the President’s Men.' New York Times Book Review
In the media
A dazzling story of deception in Silicon Valley . . . It is a tale of heroic cupidity on a scale that made the very best and the very brightest look like the very, very foolish . . . You will not be able to put this book down.
Riveting . . . a blistering critique of Silicon Valley, a kind of nonfiction corollary to Dave Eggers's The Circle . . . compelling . . . [Carreyrou's] unmasking of Theranos is a tale of David and Goliath . . . The real heroes, though, are his sources: the young scientists who worked at the company and risked their reputations and careers by voicing their concerns. Were it not for their courage, Theranos might still be testing blood today
David Crow Financial Times
I couldn’t put down this thriller with a tragic ending . . . a book so compelling that I couldn’t turn away . . . This book has everything: elaborate scams, corporate intrigue, magazine cover stories, ruined family relationships, and the demise of a company once valued at nearly $10 billion . . . No wonder Hollywood is already planning to turn it into a movie.
Bill Gates, '5 books I loved in 2018'
If you’re looking for an engaging non-fiction read, look no further than Bad Blood . . . a pacy, compelling narrative about white-collar crime that’s as incredible as any work of fiction.